Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2025-04-28 Environmental & Social …
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 1% confidence The document is titled “2024 Environmental, Social and Governance Report” and contains extensive ESG content (governance structure, material issues, environmental regulation, social initiatives, etc.). It is a standalone ESG report detailing the company’s performance on environmental, social, and governance factors. This matches the Environmental & Social Information category (Code: SR).
2025-04-28 English
2024 Annual Report
Annual Report Classification · 1% confidence The document is explicitly titled '2024 Annual Report' for Alphamab Oncology. It contains a comprehensive table of contents, including sections for the Chairman's Statement, Corporate Information, Directors' Report, Independent Auditor's Report, and full Consolidated Financial Statements (Profit or Loss, Financial Position, Changes in Equity, Cash Flows, and Notes). The document length and structure confirm it is the full annual report for the fiscal year 2024. FY 2024
2025-04-28 English
(1) GRANT OF SHARE OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME&#x3b; AND (2) GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Exchange announcement by Alphamab Oncology detailing the Board’s resolutions to grant share options under its Post-IPO Share Option Scheme and to grant award shares under its Restricted Share Award Scheme. It describes issuance terms, vesting schedules, exercise prices, and trust arrangements for newly granted options and shares. This is not a general earnings release, management discussion, or director dealing notice, but rather an announcement of share grants – an issuance of capital under the company’s incentive schemes. Accordingly, it fits the Share Issue/Capital Change category (Code: SHA).
2025-04-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Share Issue/Capital Change Classification · 1% confidence The document is an HKEX ‘Monthly Return for Equity Issuer and Hong Kong Depositary Receipts’ (Form FF301) covering movements in authorized/registered share capital, issued shares, treasury shares, share options, and related confirmations under listing rules. This is a regulatory filing specifically reporting share capital changes and movements rather than a full report (e.g., Annual or Interim) or an earnings/management presentation. It therefore falls under the Share Issue/Capital Change category (SHA).
2025-04-03 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Earnings Release Classification · 1% confidence The document is an "Annual Results Announcement" containing audited consolidated results for the year ended December 31, 2024, along with financial highlights, business highlights, events during and after the reporting period, and management discussion and analysis. It is a standalone initial announcement of the full-year financial results, analogous to an earnings release, rather than the full statutory Annual Report (10-K) or a brief interim report. Therefore, it best fits the Earnings Release category. FY 2024
2025-03-25 English
VOLUNTARY ANNOUNCEMENT - JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement by Alphamab Oncology regarding JSKN003 being granted breakthrough therapy designation by China’s NMPA. It contains no financial results, management changes, share transactions, or reporting period detail. It is a regulatory update/milestone announcement that does not fit into specific categories like earnings release, dividend notice, or report publication. Therefore, it falls under the fallback category for general regulatory announcements.
2025-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.